Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

In vivo demonstration that alpha-synuclein oligomers are toxic.

Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T, Vilar M, Campioni S, Tzitzilonis C, Soragni A, Jessberger S, Mira H, Consiglio A, Pham E, Masliah E, Gage FH, Riek R.

Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4194-9. doi: 10.1073/pnas.1100976108. Epub 2011 Feb 15.

2.

Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo.

Rockenstein E, Nuber S, Overk CR, Ubhi K, Mante M, Patrick C, Adame A, Trejo-Morales M, Gerez J, Picotti P, Jensen PH, Campioni S, Riek R, Winkler J, Gage FH, Winner B, Masliah E.

Brain. 2014 May;137(Pt 5):1496-513. doi: 10.1093/brain/awu057. Epub 2014 Mar 24.

3.

Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration.

Tsika E, Moysidou M, Guo J, Cushman M, Gannon P, Sandaltzopoulos R, Giasson BI, Krainc D, Ischiropoulos H, Mazzulli JR.

J Neurosci. 2010 Mar 3;30(9):3409-18. doi: 10.1523/JNEUROSCI.4977-09.2010.

4.

Different species of alpha-synuclein oligomers induce calcium influx and seeding.

Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretzschmar H, Hengerer B, Kostka M.

J Neurosci. 2007 Aug 22;27(34):9220-32.

5.

Mimicking phosphorylation at serine 87 inhibits the aggregation of human α-synuclein and protects against its toxicity in a rat model of Parkinson's disease.

Oueslati A, Paleologou KE, Schneider BL, Aebischer P, Lashuel HA.

J Neurosci. 2012 Feb 1;32(5):1536-44. doi: 10.1523/JNEUROSCI.3784-11.2012.

6.

alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.

Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P.

Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10813-8. Epub 2002 Jul 16.

7.

Baicalein inhibits formation of α-synuclein oligomers within living cells and prevents Aβ peptide fibrillation and oligomerisation.

Lu JH, Ardah MT, Durairajan SS, Liu LF, Xie LX, Fong WF, Hasan MY, Huang JD, El-Agnaf OM, Li M.

Chembiochem. 2011 Mar 7;12(4):615-24. doi: 10.1002/cbic.201000604. Epub 2011 Jan 26.

PMID:
21271629
8.

Curcumin modulates α-synuclein aggregation and toxicity.

Singh PK, Kotia V, Ghosh D, Mohite GM, Kumar A, Maji SK.

ACS Chem Neurosci. 2013 Mar 20;4(3):393-407. doi: 10.1021/cn3001203. Epub 2012 Dec 17.

9.

Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities.

Foguel D, Suarez MC, Ferrão-Gonzales AD, Porto TC, Palmieri L, Einsiedler CM, Andrade LR, Lashuel HA, Lansbury PT, Kelly JW, Silva JL.

Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9831-6. Epub 2003 Aug 4.

10.

Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease.

van Rooijen BD, Claessens MM, Subramaniam V.

Curr Protein Pept Sci. 2010 Aug;11(5):334-42. Review.

PMID:
20423294
11.

The interplay between lipids and dopamine on α-synuclein oligomerization and membrane binding.

Pham CL, Cappai R.

Biosci Rep. 2013 Oct 22;33(5). pii: e00074. doi: 10.1042/BSR20130092.

12.

Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease.

Sato H, Arawaka S, Hara S, Fukushima S, Koga K, Koyama S, Kato T.

J Neurosci. 2011 Nov 16;31(46):16884-94. doi: 10.1523/JNEUROSCI.3967-11.2011.

13.

Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases.

Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, Spencer B, Rockenstein E, Trejo M, Platoshyn O, Yuan JX, Masliah E.

PLoS One. 2008 Sep 4;3(9):e3135. doi: 10.1371/journal.pone.0003135.

14.

α-Synuclein oligomers impair neuronal microtubule-kinesin interplay.

Prots I, Veber V, Brey S, Campioni S, Buder K, Riek R, Böhm KJ, Winner B.

J Biol Chem. 2013 Jul 26;288(30):21742-54. doi: 10.1074/jbc.M113.451815. Epub 2013 Jun 6.

15.

Modulation of alpha-synuclein aggregation by dopamine: a review.

Leong SL, Cappai R, Barnham KJ, Pham CL.

Neurochem Res. 2009 Oct;34(10):1838-46. doi: 10.1007/s11064-009-9986-8. Epub 2009 May 15. Review.

PMID:
19444607
16.

The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.

Gorbatyuk OS, Li S, Sullivan LF, Chen W, Kondrikova G, Manfredsson FP, Mandel RJ, Muzyczka N.

Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):763-8. doi: 10.1073/pnas.0711053105. Epub 2008 Jan 4.

17.

Selection of DNA aptamers that recognize α-synuclein oligomers using a competitive screening method.

Tsukakoshi K, Abe K, Sode K, Ikebukuro K.

Anal Chem. 2012 Jul 3;84(13):5542-7. doi: 10.1021/ac300330g. Epub 2012 Jun 12.

PMID:
22697251
18.

Cellular oligomerization of alpha-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence.

Mazzulli JR, Armakola M, Dumoulin M, Parastatidis I, Ischiropoulos H.

J Biol Chem. 2007 Oct 26;282(43):31621-30. Epub 2007 Sep 4.

19.

Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease.

Lo Bianco C, Shorter J, Régulier E, Lashuel H, Iwatsubo T, Lindquist S, Aebischer P.

J Clin Invest. 2008 Sep;118(9):3087-97. doi: 10.1172/JCI35781.

20.

Single fibril growth kinetics of α-synuclein.

Wördehoff MM, Bannach O, Shaykhalishahi H, Kulawik A, Schiefer S, Willbold D, Hoyer W, Birkmann E.

J Mol Biol. 2015 Mar 27;427(6 Pt B):1428-35. doi: 10.1016/j.jmb.2015.01.020. Epub 2015 Feb 4.

PMID:
25659910

Supplemental Content

Support Center